Development of new profilers

Development of Gene Signatures into Fully Validated Diagnostic and Prognostic Tests

As an innovative company, Skyline is actively seeking academic and industrial partners for development of novel diagnostic products. If you have developed a diagnostic signature, published or unpublished, we will screen it in one month against a comprehensive set of criteria. The result of this process is a transparent scorecard, incorporating scientific value, medical benefits, as well as market considerations. If we both agree on the value of your signature, collaborative development of a novel diagnostic test is possible. We strive to reach a joint conclusion within 2 months and complete the process with a licensing agreement.